drugset / Trial / NCT03018353
Curing HCV in Incarcerated Patients
Phase 4
Unknown
100 enrolled
San Francisco Department of Public Health
Gilead Sciences · collabSan Francisco Study Center · collabUniversity of California, San Francisco · collab
NaSingle-groupOpen-labelTreatment
Summary
Curing HCV in Incarcerated Patients (CHIP) is a 1-year demonstration project that will assess the feasibility of a HCV treatment program in the San Francisco City \& County Jail. The Jail Health Services will treat 100 patients using the FDA approved combination treatment, sofosbuvir/velpatasvir, Epclusa® and will continue their treatment during incarceration and after their release (if applicable).
Timeline
- Start
- 2017-03-05
- Primary completion
- 2018-03-04
- Completion
- 2018-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sofosbuvir/velpatasvir | Unknown | — | Oral |